Integrating Quality by Design and Design of Experiments for Scalable Nanoparticle Therapeutics: A Comprehensive Review
DOI:
https://doi.org/10.22159/ijap.2026v18i5.57928Keywords:
Design of experiments (DoE), Nanoparticle, Process analytical technology (PAT), Quality by design(QbD), Regulatory frameworkAbstract
Nanoparticle-based drug delivery systems have tremendous advantages over the conventional dosage forms in terms of enhancing bioavailability, controlled release and tissue-specific targeting. However, despite great success at laboratory scale, the translation and commercialization of nanomedicines is still limited, mainly due to the inherent complexity of nanosystems, variability of the manufacturing processes and lack of globally unified regulatory frameworks. Integrating quality by design (QbD) with design of experiments (DoE) offers a scientific process for filling these gaps with more comprehensive formulation and understanding of processes. This review outlines QbD driven methodologies employed in the development of nanoparticles with a focus on the systematic determination of the quality target product profile (QTPP), critical quality attributes (CQAs), critical material attributes (CMAs), and critical process parameters (CPPs). The usefulness of DoEin screening and optimization methodology and multifactorial variables of formulation types is reviewed as a tool to derive robust design spaces and promote and provide predictive activity of nanoparticles such as particle size, polydispersity, drug loading, release kinetics, stability, etc. Updated knowledge about globally approved nanotechnology-based products is in the light of the rising clinical and regulatory acceptance of nanomedicine through various agencies. Additionally, the review summarizes key issues involving industrial implementation; from analytical limitations and barriers to the realization of the process on industrial scale, to stability issues and long-term safety evaluation; and emerging strategies including real-time monitoring, automation and advanced process control. By integrating QbD with DoE, industries can develop reproducible, efficient and scalable production processes for manufacturing nanoparticles.
References
1. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905. doi:10.3390/molecules26195905.
2. Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery–A review. Results in Surfaces and Interfaces. 2025;19:100529. doi:10.1016/j.rsurfi.2025.100529.
3. Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arabian Journal of Chemistry. 2019;12(7):908–31. doi:10.1016/j.arabjc.2017.05.011.
4. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291-7309. doi:10.2147/ijn.s146315.
5. Jia Y, Jiang Y, He Y, Zhang W, Zou J, Magar KT, Boucetta H, Teng C, He W. Approved nanomedicine against diseases. Pharmaceutics. 2023;15(3):774. doi:10.3390/pharmaceutics15030774.
6. Halwani AA. Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics. 2022;14(1):106. doi:10.3390/pharmaceutics14010106.
7. GabizonAA, Gabizon-Peretz S, Modaresahmadi S, La-Beck NM. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. BMJ Oncology. 2025;4:e000573. doi:10.1136/bmjonc-2024-000573.
8. Kumar A, Shahvej SK, Yadav P, Modi U, Yadav AK, Solanki R, Bhatia D. Clinical applications of targeted nanomaterials. Pharmaceutics. 2025;17(3):379. doi:10.3390/pharmaceutics17030379.
9. Namiot ED, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB. Nanoparticles in clinical trials: analysis of clinical trials, fda approvals and use for covid-19 vaccines. Int J Mol Sci. 2023;24(1):787. doi:10.3390/ijms24010787.
10. Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, Rovira R, Ruiz R, Martín-Lorente C, Corchero JL, Céspedes MV. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022;12(6):784. doi:10.3390/biom12060784.
11. IMARC Group. Nanomedicine market size, share, growth report 2025–2033 [Internet]. Pune (India): IMARC Group; 2024 [cited 2025 Oct 29]. Available from: https://www.imarcgroup.com/nanomedicine-market
12. Precedence Research. Nanomedicine market size to hit USD 627.03 billion by 2034 [Internet]. Ottawa (Canada): Precedence Research; 2024 [cited 2025 Oct 29]. Available from: https://www.precedenceresearch.com/nanomedicine-market
13. Nadeem AY, Shehzad A, Islam SU, Al-Suhaimi EA, Lee YS. MosquirixTM RTS, S/AS01 vaccine development, immunogenicity, and efficacy. Vaccines. 2022;10(5):713. doi:10.3390/vaccines10050713.
14. CSPC Pharmaceutical Group. SYHX2011 nano-formulation approval by China National Medical Products Administration [Internet]. Shijiazhuang (China): CSPC Pharmaceutical Group; 2024 Dec 8 [cited 2025 Nov 5]. Available from: https://www.cspc.com.hk/en/ir/presentations/20251Q.pdf
15. U.S. Food and Drug Administration. FDA approves EMRELIS (telisotuzumabvedotin-tllv) for adults with previously treated advanced non-small cell lung cancer [Internet]. Silver Spring (MD): FDA; 2025 May 14 [cited 2025 Nov 5]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emrelis-telisotuzumab-vedotin-tllv-adults-previously-treated-advanced-non-small-cell-lung-cancer
16. U.S. Food and Drug Administration. FDA grants accelerated approval to Datroway (datopotamabderuxtecan-dlnk) for unresectable or metastatic breast cancer [Internet]. Silver Spring (MD): FDA; 2025 Jan 16 [cited 2025 Nov 5]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer
17. Imam SS. Nanoparticles: the future of drug delivery. Int J Curr Pharm Res. 2023;15(6):8–15. doi:10.22159/ijcpr.2023v15i6.3076.
18. Bar H, Bhui DKr, Sahoo GP, Sarkar P, De SP, Misra A. Green synthesis of silver nanoparticles using latex of Jatrophacurcas. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2009;339(1–3):134–9. doi:10.1016/j.colsurfa.2009.02.008.
19. Lin RH, Lee HT, Yeh CA, Yang YC, Shen CC, Chang KB, et al. Favorablebiological performance regarding the interaction between gold nanoparticles and mesenchymal stem cells. Int J Mol Sci 2022;24(1):5. doi:10.3390/ijms24010005.
20. Karnwal A, Kumar Sachan RS, Devgon I, Devgon J, Pant G, Panchpuri M, et al. Gold nanoparticles in nanobiotechnology: from synthesis to biosensing applications. ACS Omega. 2024;9(28):29966-29982. doi:10.1021/acsomega.3c10352.
21. Tambve AB, Jadhav PD, Ghotkar MN, Chougule AS, Borkar SP. A review on nanoparticles. Asian Journal of Pharmacy and Technology. 2020;10(2):118. doi:10.5958/2231-5713.2020.00020.3.
22. Ceylan A, Jastrzembski K, Shah SI. Enhanced solubility Ag-Cu nanoparticles and their thermal transport properties. Metallurgical and Materials Transactions A. 2006;37(7):2033–8. doi:10.1007/BF02586123.
23. Huynh KH, Pham XH, Kim J, Lee SH, Chang H, Rho WY, Jun BH. Synthesis, properties, and biological applications of metallic alloy nanoparticles. Int J Mol Sci. 2020;21(14):5174. doi:10.3390/ijms21145174.
24. Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett. 2012;7(1):144. doi:10.1186/1556-276X-7-144.
25. Ghazi R, Ibrahim TK, Nasir JA, Gai S, Ali G, Boukhris I, Rehman Z. Iron oxide based magnetic nanoparticles for hyperthermia, MRI and drug delivery applications: a review. RSC Adv. 2025;15(15):11587-11616. doi:10.1039/d5ra00728c.
26. Beg S, Rahman M, Kohli K. Quality-by-design approach as a systematic tool for the development of nanopharmaceutical products. Drug Discovery Today. 2019;24(3):717–25. doi:10.1016/j.drudis.2018.12.002.
27. Duarte JG, Duarte MG, Piedade AP, Mascarenhas-Melo F. Rethinking pharmaceutical industry with quality by design: application in research, development, manufacturing, and quality assurance. The AAPS Journal. 2025;27(4):96. doi:10.1208/s12248-025-01079-w.
28. Politis NS, Colombo P, Colombo G, M Rekkas D. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43(6):889-901. doi:10.1080/03639045.2017.1291672.
29. Yang S, Hu X, Zhu J, Zheng B, Bi W, Wang X, Wu J, Mi Z, Wu Y. Aspects and implementation of pharmaceutical quality by design from conceptual frameworks to industrial applications. Pharmaceutics. 2025;17(5):623. doi:10.3390/pharmaceutics17050623.
30. Bhavyasri K, Reddy AB, Sumakanth M. Analytical methods for quality control of nanoformulations-a review. Asian J Pharm Clin Res. 2023;16(10):1-6. doi:10.22159/ajpcr.2023.v16i10.48073.
31. Kaleem AM, Koilpillai J, Narayanasamy D. Mastering quality: uniting risk assessment with quality by design (QbD) principles for pharmaceutical excellence. Cureus. 2024;16(8):e68215. doi:10.7759/cureus.68215.
32. Tavares Luiz M, Santos Rosa Viegas J, Palma Abriata J, Viegas F, TestaMoura de CarvalhoVicentini F, Lopes Badra Bentley MV, et al. Design of experiments (DoE) to develop and to optimize nanoparticles as drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics. 2021;165:127–48. doi:10.1016/j.ejpb.2021.05.011.
33. Zhu Z. Intelligent information management enables quality-by-design in pharmaceutical production. Sci Rep. 2025;15(1):44201. doi:10.1038/s41598-025-27879-w.
34. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771-83. doi:10.1208/s12248-014-9598-3.
35. Simões A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: an enhanced quality approach. European Journal of Pharmaceutics and Biopharmaceutics. 2024;195:114174. doi:10.1016/j.ejpb.2023.114174.
36. Dri DA, Rinaldi F, Carafa M, Marianecci C. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes. Drug DelivTransl Res. 2023;13(3):757-769. doi:10.1007/s13346-022-01262-y.
37. Nogueira SS, Samaridou E, Simon J, Frank S, Beck-Broichsitter M, Mehta A. Analytical techniques for the characterization of nanoparticles for mRNA delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2024;198:114235. doi:10.1016/j.ejpb.2024.114235.
38. Dias AL, Ferreira NN, Ferreira LMB, Pedreiro LN, dos Santos AM, Gremião MPD. Regulation of nanotechnology-based products subject to health regulations: application of quality by design and quality risk management. In: Grumezescu AM, editor. Quality by design for pharmaceuticals. Cham (Switzerland): Springer; 2021. p. 319–347. doi:10.1007/978-3-030-63389-9_13.
39. Rezaei F, Yarmohammadian MH, Haghshenas A, Fallah A, Ferdosi M. Revised risk priority number in failure mode and effects analysis model from the perspective of healthcare system. Int J Prev Med. 2018;9:7. doi:10.4103/2008-7802.224046.
40. Waghule T, Dabholkar N, Gorantla S, Rapalli VK, Saha RN, Singhvi G. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): a risk based industrial approach. Biomedicine and Pharmacotherapy. 2021;141:111940. doi:10.1016/j.biopha.2021.111940.
41. Lemmens SMP, Lopes van Balen VA, Röselaers YCM, Scheepers HCJ, Spaanderman MEA. The risk matrix approach: a helpful tool weighing probability and impact when deciding on preventive and diagnostic interventions. BMC Health Serv Res. 2022;22(1):218. doi:10.1186/s12913-022-07484-7.
42. Camacho Vieira C, Peltonen L, Karttunen AP, Ribeiro AJ. Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration? Int J Pharm. 2024;657:124163. doi:10.1016/j.ijpharm.2024.124163.
43. Hidayat AF, Wardhana YW, Suwendar S, Mohammed AFA, Mahmoud SA, Elamin KM, Wathoni N. A review on QbD-driven optimization of lipid nanoparticles for oral drug delivery: from framework to formulation. Int J Nanomedicine. 2025;20:8611-8651. doi:10.2147/IJN.S534137.
44. Bhattacharya S. Central composite design for response surface methodology and its application in pharmacy. in: response surface methodology in engineering science [Internet]. London: IntechOpen; 2021. doi:10.5772/intechopen.95835.
45. Porwal O. Box-behnken design-based formulation optimization and characterization of spray dried rutin loaded nanosuspension: state of the art. South African Journal of Botany. 2022;149:807–15. doi:10.1016/j.sajb.2022.04.028.
46. Morris MD. A class of three-level experimental designs for response surface modeling. Technometrics. 2000;42(2):111–21. doi:10.1080/00401706.2000.10485990.
47. Kefi BB, Nefzi K, Koumba S, M'Hamdi N, Martin P. Application of doehlert experimental design for optimization of a new-based hydrophilic interaction solid-phase extraction of phenolic acids from olive oils. Molecules. 2023;28(3):1073. doi:10.3390/molecules28031073.
48. Ekpenyong MG, Antai SP, Asitok AD, Ekpo BO. Plackett-burman design and response surface optimization of medium trace nutrients for glycolipopeptide biosurfactant production. Iran Biomed J. 2017;21(4):249–60. doi:10.18869/acadpub.ibj.21.4.249.
49. de Souza HJC, Borges M, Moyses CB, Lopes FJF, Ferreira UR. Robust design and taguchi method application. in: design of experiments – applications [Internet]. London: IntechOpen; 2013. doi:10.5772/56580.
50. Szpisják-Gulyás N, Al-Tayawi AN, HorváthZsH, LászlóZs, KertészSz, Hodúr C. Methods for experimental design, central composite design and the Box–Behnken design, to optimise operational parameters: a review. Acta Aliment. 2023;52(4):521–37. doi:10.1556/066.2023.00235.
51. Liu X, Atwater M, Wang J, Dai Q, Zou J, Brennan JP, et al. A study on gold nanoparticle synthesis using oleylamine as both reducing agent and protecting ligand. J NanosciNanotechnol. 2007;7(9):3126–33. doi:10.1166/jnn.2007.805.
52. As’adi MHA, Kuncahyo I, Sulaiman TNS. Formulation of fenofibrate nanocrystals with wet milling method. RisetInformasiKesehatan. 2023;12(1):50. doi:10.30644/rik.v12i1.761.
53. Fazil MM, Gul A, Jawed H. Optimization of silver nanoparticles synthesis via plackett–burmanexperimental design: in vitro assessment of their efficacy against oxidative stress-induced disorders. RSC Adv. 2024;14(29):20809–23. doi:10.1039/d4ra02774d.
54. PeriaswamySivagnanam S, Tilahun Getachew A, Choi JH, Park YB, Woo HC, Chun BS. Green synthesis of silver nanoparticles from deoiled brown algal extract via box-behnken based design and their antimicrobial and sensing properties. Green Processing and Synthesis. 2017;6(2):147–60. doi:10.1515/gps-2016-0052.
55. Buya AB, Mahlangu P, Witika BA. From lab to industrial development of lipid nanocarriers using quality by design approach. Int J Pharm X. 2024;8:100266. doi:10.1016/j.ijpx.2024.100266.
56. Zagalo DM, Silva BMA, Silva C, Simões S, Sousa JJ. A quality by design (QbD) approach in pharmaceutical development of lipid-based nanosystems: a systematic review. J Drug DelivSci Technol. 2022;70:103207. doi:10.1016/j.jddst.2022.103207.
57. R. Patil D, K. Patil D, A. Patil S. A review on quality by design. Research Journal of Pharmacology and Pharmacodynamics. 2024;119–22. doi:10.52711/2321-5836.2024.00021.
58. Jain S. Quality by design (QbD): A comprehensive understanding of implementation and challenges in pharmaceuticals development. Int J Pharm Pharm Sci. 2014;6(1):29–35.
59. Aru PB, Gulhane MS, Katekar VA, Deshmukh SP. Quality by design (QbD) in pharmaceutical development: a comprehensive review. GSC Biological and Pharmaceutical Sciences. 2024;26(1):328–40. doi:10.30574/gscbps.2024.26.1.0019.
60. Gandhi A, Roy C. Quality by Design (QbD) in pharmaceutical industry: tools, perspectives and challenges. PharmaTutor. 2016;4(11):12–20.
61. Pai AB. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation. Ann N Y Acad Sci. 2017;1407(1):17-25. doi:10.1111/nyas.13461.
62. Kapadia R, Shevalkar G, Das U, Singhai V, Bari D, Pardeshi CV. Introduction to quality by design. In: introduction to quality by design (QbD). Singapore: Springer Nature; 2024. p. 1–33.doi:10.1007/978-981-99-8034-5_1.
63. Xuan L, Ju Z, Skonieczna M, Zhou PK, Huang R. Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. MedComm. 2023;4(4):e327. doi:10.1002/mco2.327.
64. Giannakou C, Park MVDZ, Bosselaers IEM, de Jong WH, van der Laan JW, van Loveren H, et al. Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls. Wiley Interdiscip Rev NanomedNanobiotechnol. 2020;12(5):e1633. doi:10.1002/wnan.1633.
65. Kelle D, Speth KR, Martínez-Negro M, Mailänder V, Landfester K, Iyisan B. Effect of protein corona on drug release behavior of PLGA nanoparticles. Eur J Pharm Biopharm. 2025;207:114611. doi:10.1016/j.ejpb.2024.114611.
66. Wang Y, Wu Q, Wang J, Li L, Sun X, Zhang Z, Zhang L. Co-delivery of p38α MAPK and p65 siRNA by novel liposomal glomerulus-targeting nano carriers for effective immunoglobulin a nephropathy treatment. J Control Release. 2020;320:457-468. doi:10.1016/j.jconrel.2020.01.024.
67. Laurent A. ICH Q8 explained: a guide to pharmaceutical development and quality by design [Internet]. IntuitionLabs; 2026March 30 [cited 2025 Nov 25]. Available from: https://intuitionlabs.ai/articles/ich-q8-pharmaceutical-development
68. van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007-1017. doi:10.1038/s41565-019-0567-y.
69. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7.
70. Liu G, Lovell JF, Zhang L, Zhang Y. Stimulus-responsive nanomedicines for disease diagnosis and treatment. Int J Mol Sci. 2020;21(17):6380. doi:10.3390/ijms21176380.
71. Salem SS. A mini review on green nanotechnology and its development in biological effects. Arch Microbiol. 2023;205(4):128. doi:10.1007/s00203-023-03467-2.
72. Abughalia A, Flynn M, Clarke PFA, Fayne D, Gobbo OL. The use of computational approaches to design nanodelivery systems. Nanomaterials (Basel). 2025;15(17):1354. doi:10.3390/nano15171354.
Published
How to Cite
Issue
Section
Copyright (c) 2026 AMIT KUMAR, POOJA B., AMITHA SHETTY, AKHILESH DUBEY
This work is licensed under a Creative Commons Attribution 4.0 International License.